The average one-year price target for Bio-Rad Laboratories (NYSE:BIO) has been revised to $362.10 / share. This is an increase of 14.15% from the prior estimate of $317.22 dated November 7, 2025.
The price target is an average of many targets provided by analysts. The latest targets range from a low of $328.25 to a high of $393.75 / share. The average price target represents an increase of 15.63% from the latest reported closing price of $313.15 / share.
What is the Fund Sentiment?
There are 806 funds or institutions reporting positions in Bio-Rad Laboratories. This is an increase of 5 owner(s) or 0.62% in the last quarter. Average portfolio weight of all funds dedicated to BIO is 0.27%, an increase of 4.52%. Total shares owned by institutions increased in the last three months by 1.93% to 25,998K shares. 
The put/call ratio of BIO is 2.56, indicating a bearish outlook.
What are Other Shareholders Doing?
First Eagle Investment Management holds 2,520K shares representing 11.50% ownership of the company. In its prior filing, the firm reported owning 2,517K shares , representing an increase of 0.12%. The firm increased its portfolio allocation in BIO by 4.96% over the last quarter.
SGENX - First Eagle Global Fund holds 1,879K shares representing 8.58% ownership of the company. In its prior filing, the firm reported owning 1,653K shares , representing an increase of 12.01%. The firm increased its portfolio allocation in BIO by 5.32% over the last quarter.
Veritas Asset Management LLP holds 844K shares representing 3.85% ownership of the company. In its prior filing, the firm reported owning 863K shares , representing a decrease of 2.26%. The firm increased its portfolio allocation in BIO by 21.33% over the last quarter.
Ariel Investments holds 809K shares representing 3.70% ownership of the company. In its prior filing, the firm reported owning 819K shares , representing a decrease of 1.13%. The firm increased its portfolio allocation in BIO by 4.17% over the last quarter.
VTSMX - Vanguard Total Stock Market Index Fund Investor Shares holds 616K shares representing 2.81% ownership of the company. In its prior filing, the firm reported owning 614K shares , representing an increase of 0.32%. The firm decreased its portfolio allocation in BIO by 11.32% over the last quarter.
Fintel is one of the most comprehensive investing research platforms available to individual investors, traders, financial advisors, and small hedge funds.
Our data covers the world, and includes fundamentals, analyst reports, ownership data and fund sentiment, options sentiment, insider trading, options flow, unusual options trades, and much more. Additionally, our exclusive stock picks are powered by advanced, backtested quantitative models for improved profits.
This story originally appeared on Fintel.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
